Neutralization of Oxidative Stress Markers
Johnston, R
In a Phase 2b study in people with type 2 diabetes and obesity over 54 weeks, treatment with cotadutide at doses of 100-300 g daily improved some non-invasive markers of NAFLD such as transaminase levels, the FIB-4 index, fatty liver disease fibrosis score (NFS) and fatty liver index (FLI) but fatty liver disease was not assessed directly with liver biopsy
In preclinical models, GLP-1s have been shown to reduce alcohol, nicotine, opioid, and cocaine intake, and not just consumption, but also the drive to seek those substances out
Gentle Treatment: Applied with precision and care, ensuring a soothing experience
Last Published 01.01.2026 Effective Date: 01.01.2026 This policy addresses the use of Gamifant (emapalumab-lzsg) for the treatment of primary and secondary hemophagocytic lymphohistiocytosis (HLH)